Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

INTERVIEW: Tapping China Expertise, Market Core To Celsion’s ThermoDox Plans

This article was originally published in PharmAsia News

Executive Summary

Celsion, a US company specialized in oncology, is advancing its new China OPTIMA study with ThermoDox, a doxorubicin preparation for primary liver cancer. CEO Michael Tardugno sat down with PharmAsia News to talk about the ongoing clinical process and the Nasdaq-listed firm’s broader development and commercial plans, in which China plays a key role.



Related Companies